Cryoport's Profitability Pivot: The Cold Chain Backbone of Gene Therapy

NASHVILLE, TN – August 06, 2026 – Cryoport, Inc. today announced what its leadership heralds as a significant milestone on its "pathway to profitability": achieving a positive adjusted EBITDA. While the headline figure of $0.4 million is modest, its importance lies in the directional shift it represents for a company that has been investing heavily to become the indispensable logistical backbone for the cell and gene therapy (CGT) revolution. The company reported an 8% year-over-year revenue increase to $49.0 million for the second quarter, but the critical assessment for investors and industry observers hinges on whether this pivot to profitability is sustainable or merely a non-GAAP footnote to a still-unprofitable enterprise.

For years, Cryoport's story has been one of growth and investment, building a complex, temperature-controlled global supply chain to support the world’s most advanced and sensitive medicines. This quarter's results suggest that the strategy may be entering a new phase, where the operating leverage from those investments begins to materialize. Yet, with a GAAP net loss of $8.3 million for the quarter, the journey to true, sustainable profitability is far from over. The numbers present a dual narrative: one of a maturing business reaching a crucial inflection point, and another of the steep, continuing costs of enabling the future of medicine.

The Anatomy of a Profitability Pivot

A critical analysis of Cryoport's financials reveals the widening gap between its operational performance and its bottom-line accounting. The achievement of a positive adjusted EBITDA of $0.4 million, a notable improvement from a negative $0.9 million in the same quarter last year, is the result management wants to highlight. CEO Jerrell Shelton stated, "Achieving positive adjusted EBITDA in the second quarter represents an important milestone in our ongoing pathway to sustainable profitability and demonstrates the value of our strategic investments and operational initiatives." This non-GAAP metric strips out non-cash expenses like depreciation and amortization, as well as interest, taxes, and other one-off costs, to offer a clearer view of the core business's cash-generating ability.

The discrepancy with the $8.3 million GAAP net loss is stark but understandable. The net loss is heavily influenced by the depreciation of the very infrastructure—global supply chain centers, specialized cryogenic equipment—that forms the company's competitive moat. These are the costs of building the rails before the trains can run at full capacity. The more telling metric, perhaps, is the company's operating cash flow, which was positive $5 million in the first half of 2026, a $17 million improvement over the prior year. This suggests that the business is, in fact, beginning to generate more cash than it consumes in its day-to-day operations, lending credibility to the positive adjusted EBITDA figure.

Growth was primarily fueled by the Life Sciences Services segment, which saw revenue climb 15% to $28.0 million. Within that, the BioStorage/BioServices unit was a standout performer, growing 25% year-over-year. This indicates strong demand for the company’s integrated offering beyond simple logistics. In contrast, the Life Sciences Products segment remained flat. This divergence underscores that Cryoport's future is inextricably linked to its role as a service provider at the heart of the biopharma ecosystem, rather than just a seller of equipment.

The Engine Room: Riding the Cell and Gene Therapy Wave

Beyond the financial metrics, the real narrative is found in Cryoport's deepening entrenchment in the cell and gene therapy market. The company now supports a record 779 clinical trials globally, a net increase of 51 from the previous year. Crucially, 94 of these trials are in Phase 3, the final stage before potential commercial approval. This pipeline represents a formidable leading indicator of future revenue, as each therapy that successfully moves from clinical trial to commercial product becomes a recurring, long-term revenue stream for Cryoport.

The company's support for therapies already on the market is accelerating. Revenue from commercial CGT support grew 9% overall, but the services component of that revenue jumped an impressive 26%. This surge is driven by the increasing number of patients being treated in community and outpatient settings, a logistical challenge that plays directly to Cryoport’s strengths in managing complex, time-and-temperature sensitive shipments to diverse points of care.

This quarter saw tangible results from its client pipeline. Cryoport supported Orca Bio in securing FDA approval for TREGZI™, a first-of-its-kind cell therapy for stem cell transplant patients. It also supported Vertex Pharmaceuticals in gaining an expanded FDA label for CASGEVY®, a groundbreaking gene therapy for sickle cell disease and beta thalassemia, now approved for children as young as two. These successes are not just wins for Cryoport's customers; they are validations of Cryoport's own business model, proving its platform is essential for bringing these transformative treatments to patients. With a forecast of 11 more potential regulatory filings and five new therapy approvals from its client base in the second half of 2026, the engine of growth shows no signs of slowing.

Building the Rails for Regenerative Medicine

Cryoport's journey to profitability is directly tied to the utilization of its expanding global footprint. The company is making significant progress on key infrastructure projects, with its new Global Supply Chain Center in Paris expected to launch BioServices operations in the fourth quarter, and a state-of-the-art facility in Santa Ana, California, also slated to open later this year. These centers are more than just warehouses; they are highly specialized, regulated facilities designed for cryopreservation, storage, and distribution, forming the core of a standardized global network.

Furthermore, the company announced the first shipment of its proprietary HE freezers from its manufacturing facility in Chengdu, a strategic move to serve the Chinese market locally. This "made in China for China" approach aims to circumvent potential tariffs and solidify its competitive position in the burgeoning APAC life sciences market. While China currently represents a small fraction of revenue, this move signals a long-term strategic commitment.

These investments are the foundation for the operating leverage that management frequently references. As these centers come online and client volumes increase, each additional dollar of revenue should, in theory, contribute more to the bottom line, as the fixed costs of the infrastructure are already in place. The key challenge ahead will be to fill this new capacity efficiently. The success of this transition—from building the infrastructure to maximizing its utilization—will ultimately determine whether Cryoport can convert non-GAAP milestones into sustained, GAAP-level profitability and deliver on its promise of long-term shareholder value.